About
Immuno-oncology, synthetic dsRNA complex
Areas of Focus
Categories
Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide Therapy
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
4
As Collaborator
3
Total Enrollment
209
By Phase
PHASE2: 3PHASE1/PHASE2: 1EARLY_PHASE1: 1PHASE1: 2
By Status
TERMINATED: 2ACTIVE_NOT_RECRUITING: 2RECRUITING: 1UNKNOWN: 1COMPLETED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06422936Lead Sponsor
Clinical Trial to Evaluate BO-112 in Patients with Basal Cell Carcinoma (BCC)
PHASE2Recruiting
60 participants
Started: May 27, 2024 · Completed: Jun 30, 2028
NCT05265650Collaborator
Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC
PHASE1/PHASE2Unknown
30 participants
Started: Jun 13, 2022 · Completed: Jun 30, 2024
NCT04777708Collaborator
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
EARLY_PHASE1Terminated
1 participants
Started: Oct 13, 2021 · Completed: Mar 13, 2023
NCT04570332Lead Sponsor
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
PHASE2Active, not recruiting
42 participants
Started: Dec 30, 2020 · Completed: Aug 1, 2024
NCT04420975Collaborator
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
PHASE1Active, not recruiting
14 participants
Started: Oct 14, 2020 · Completed: Jan 31, 2027
Locations (1)
Headquarters
Valencia, Spain
Map
Loading map...